{
  "id": 15905649,
  "title": "Arcus kidney cancer data impresses analysts; TriGemX inks a SPAC deal",
  "url": "https://urgent.news/2026/10/21/arcus-kidney-cancer-data-impresses-analysts-trigemx-inks-a-spac-deal",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-21T14:23:00.000Z",
  "source": {
    "name": "BioPharma Dive",
    "slug": "biopharma-dive",
    "url": "https://www.biopharmadive.com/news/arcus-casdatifan-trigemx-lilly-metis-astrazeneca/833430/"
  },
  "original_language": "en",
  "account": null,
  "summary": "New follow-up results suggest Arcus’ drug might be superior to a marketed Merck medicine. Elsewhere, Eli Lilly and AstraZeneca forged new partnerships.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}